西南医科大学学报2025，Vol.48Issue(2)：206-209,4.DOI:10.3969/j.issn.2096-3351.2025.02.015
NLR+iMELD对乙型肝炎慢加急性肝衰竭患者预后的评估价值
Prognosis Value of NLR+iMELD in Hepatitis B Virus(HBV)-Related Acute-on-Chronic Liver Failure
摘要
Abstract
Objective To investigate the prognostic value of the neutrophil-to-lymphocyte ratio(NLR)combined with the inte-grated model for end-stage liver disease incorporating serum sodium and age(iMELD)in assessing the prognosis of hepatitis B virus-related acute-on-chronic liver failure(HBV-ACLF).Methods A total of 126 HBV-ACLF patients were analyzed and divided into a survival group(72 cases)and a death group(54 cases)based on their 90-day prognosis.Upon admission to the hospital,liver function tests,serum creatinine levels,coagulation profiles,serum sodium ion levels,and complete blood counts were collected,and the patients'age and gender were recorded.The Neutrophil-to-Lymphocyte Ratio(NLR)and Model for End-stage Liver Disease(MELD)scores were calculated based on the relevant indicators.Multivariate logistic regression was used to analyze the relationship between each scoring system and the disease outcome of HBV-ACLF patients.Receiver operating characteristic(ROC)curves were plotted to analyze the area under the ROC curve(AUC)for NLR+iMELD,examining the correlation between NLR+iMELD scores and the prognosis of HBV-ACLF patients.Results The NLR,iMELD scores in the death group of HBV-ACLF patients were(3.507±0.726,43.13±7.58),respectively,all higher than those in the survival group(2.850±0.557,34.08±8.41)(P<0.001).The AUC indi-cated that the AUC for NLR was 0.745(95%CI:0.657～0.833);for iMELD,it was 0.792(95%CI:0.714～0.870);and the com-bined NLR+iMELD had the highest AUC at 0.865(95%CI:0.800～0.930).Conclusion The NLR+iMELD showed significant prognostic value and clinical guidance for patients with HBV-ACLF.关键词
慢加急性肝衰竭/预后评估/中性粒细胞与淋巴细胞比值/终末期肝病血清钠年龄模型Key words
Acute-on-chronic liver failure/Prognosis/Neutrophil-to-lymphocyte ratio/Integrated model for end-stage liver disease分类
医药卫生引用本文复制引用
钱珍,辛雪萍,张威,张帆,王帅..NLR+iMELD对乙型肝炎慢加急性肝衰竭患者预后的评估价值[J].西南医科大学学报,2025,48(2):206-209,4.基金项目
河南省医学科技攻关计划(联合共建)项目(LHGJ20191256) （联合共建）
洛阳市科技计划项目(1970001A) （1970001A）
佑安肝病感染病专科医疗联盟科研专项经费资助项目(LM202007) （LM202007）
